Amrinone - CAS 60719-84-8
Catalog number: B0084-072903
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C10H9N3O
Molecular Weight:
187.20
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
Amrinone is a selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. It is a simple, non-glycoside cardiotonic agent. It provides protection against ischemia-reperfusion injury in kidney, liver, and heart. It has the ability to stimulate calcium ion influx into the cardiac cell. It is used in the treatment of congestive heart failure. It increases cardiac contractility as a vasodilator. It acts by inhibiting the breakdown of both cAMP and cGMP by the phosphodiesterase (PDE3) enzyme. It is a drug that may improve the prognosis in patients with congestive heart failure. It has been shown to increase the contractions initiated in the heart by high gain calcium induced calcium release (CICR). It was developed by Sanofi and has been listed.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-072903 2.5 g $198 In stock
B0084-072903 5 g $348 In stock
Bulk Inquiry
Purity:
98%
Appearance:
Pale Beige to Yellow Solid
Synonyms:
Inamrinone;Wincoram;Inocor;Cordemcura;Win-40680;Win40680;3-Amino-5-pyridin-4-yl-1H-pyridin-2-one
Solubility:
DMSO (Slightly), Methanol (Slightly)
Storage:
2-8°C
MSDS:
Inquire
Application:
Amrinone is a simple, non-glycoside cardiotonic agent. It provides protection against ischemia-reperfusion injury in kidney, liver, and heart. It is used in the treatment of congestive heart failure. It increases cardiac contractility as a vasodilator.
Quality Standard:
CP standard
Quantity:
Kilograms to Tons
Boiling Point:
451.5±45.0 °C | Condition: Press: 760 Torr
Melting Point:
295 °C (decomp)
Density:
1.277±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
RNLQIBCLLYYYFJ-UHFFFAOYSA-N
InChI:
InChI=1S/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)
Canonical SMILES:
C1=CN=CC=C1C2=CNC(=O)C(=C2)N
Current Developer:
Amrinone was developed by Sanofi and has been listed.
1.A Systematic Review of Topical Vasodilators for the Treatment of Intraoperative Vasospasm in Reconstructive Microsurgery.
Vargas CR1, Iorio ML, Lee BT. Plast Reconstr Surg. 2015 Aug;136(2):411-22. doi: 10.1097/PRS.0000000000001431.
BACKGROUND: Intraoperative vasospasm during reconstructive microsurgery is common, often unpredictable, and potentially devastating with regard to flap survival. Current methods of pharmacologic management vary, and may be shifting as a result of changes in the availability of individual medications. This review aims to provide a concise examination of the published literature regarding use, efficacy, and adverse effects of the agents described for local management of vascular spasm during microsurgery.
2.ANP and CNP activate CFTR expressed in Xenopus laevis oocytes by direct activation of PKA.
Stahl K1,2, Stahl M1,2, de Jonge HR2,3, Forrest JN Jr1,2. J Recept Signal Transduct Res. 2015;35(5):493-504. doi: 10.3109/10799893.2015.1015738. Epub 2015 May 27.
CONTEXT: Acting through different receptors, natriuretic peptides (atrial natriuretic peptide [ANP], brain type natriuretic peptide [BNP] and C-type natriuretic peptide [CNP]) increase intracellular cGMP, which then stimulates different pathways that activate fluid secretion.
3.The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium.
Guth BD1, Chiang AY2, Doyle J3, Engwall MJ4, Guillon JM5, Hoffmann P6, Koerner J7, Mittelstadt S8, Ottinger S9, Pierson JB10, Pugsley MK11, Rossman EI12, Walisser J13, Sarazan RD3. J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:70-90. doi: 10.1016/j.vascn.2015.02.002. Epub 2015 Apr 3.
INTRODUCTION: Drug-induced effects on the cardiovascular system remain a major cause of drug attrition. While hemodynamic (blood pressure (BP) and heart rate (HR)) and electrophysiological methods have been used in testing drug safety for years, animal models for assessing myocardial contractility are used less frequently and their translation to humans has not been established. The goal of these studies was to determine whether assessment of contractility and hemodynamics, when measured across different laboratories using the same protocol, could consistently detect drug-induced changes in the inotropic state of the heart using drugs known to have clinically relevant positive and negative effects on myocardial contractility.
4.Alcohols as alkylating agents in heteroarene C-H functionalization.
Jin J1, MacMillan DW1. Nature. 2015 Sep 3;525(7567):87-90. doi: 10.1038/nature14885. Epub 2015 Aug 26.
Redox processes and radical intermediates are found in many biochemical processes, including deoxyribonucleotide synthesis and oxidative DNA damage. One of the core principles underlying DNA biosynthesis is the radical-mediated elimination of H2O to deoxygenate ribonucleotides, an example of 'spin-centre shift', during which an alcohol C-O bond is cleaved, resulting in a carbon-centred radical intermediate. Although spin-centre shift is a well-understood biochemical process, it is underused by the synthetic organic chemistry community. We wondered whether it would be possible to take advantage of this naturally occurring process to accomplish mild, non-traditional alkylation reactions using alcohols as radical precursors. Because conventional radical-based alkylation methods require the use of stoichiometric oxidants, increased temperatures or peroxides, a mild protocol using simple and abundant alkylating agents would have considerable use in the synthesis of diversely functionalized pharmacophores.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


CAS 60719-84-8 Amrinone

Amrinone
(CAS: 60719-84-8)

Amrinone is a selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. It is a simple, non-glycoside cardiotonic ag...

JNJ-10258859
(CAS: 374927-03-4)

JNJ-10258859 is a novel, potent, and selective phosphodiesterase type 5 inhibitor 5 with a K(i) of 0.23 nM and displayed excellent selectivity versus phosphodie...

CAS 141184-34-1 Filaminast

Filaminast
(CAS: 141184-34-1)

Filaminast is a Type 4 cyclic nucleotide phosphodiesterase inhibitor. It is an analog of rolipram which served as a prototype molecule for several development e...

CAS 189362-06-9 K134

K134
(CAS: 189362-06-9)

K134 is a selective phosphodiesterase 3 (PDE3) inhibitor, and has been shown to exhibit more potent anti-platelet activity than cilostazol. In vivo studies have...

CAS 192767-01-4 L791943

L791943
(CAS: 192767-01-4)

L791943 is a highly potent and metabolically stable PDE4 inhibitor with good in vitro activity (IC50= 4.2 nM). L-791, 943 is potent in vitro and in vivo as demo...

CAS 78415-72-2 Milrinone

Milrinone
(CAS: 78415-72-2)

Milrinone is a phosphodiesterase 3 (PDE3) inhibitor with vasodilator properties, used to increase the heart's contractility. It increases erythrocyte cAMP activ...

CAS 1082743-70-1 PDE-9 inhibitor

PDE-9 inhibitor
(CAS: 1082743-70-1)

PDE-9 inhibitor is useful for neurodegenerative diseases.

CAS 58337-38-5 EHNA hydrochloride

EHNA hydrochloride
(CAS: 58337-38-5)

EHNA hydrochloride is a selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 μM) and also an inhibitor of adenosine deaminase. EHNA i...

Chemical Structure

CAS 60719-84-8 Amrinone

Quick Inquiry

Verification code

Featured Items